Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
November 6, 2023 4:01 PM ESTRoyalty Revenue Increased 15% YOY to Record $114.4 million
Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR
GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.751
Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430-$445 million and Non-GAAP EPS Guidance to $2.70-$2.80Â Â Â Â
SAN DIEGO, Nov. 6,... More
